Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 1
1984 4
1985 2
1986 1
1987 2
1988 2
1989 2
1990 3
1991 1
1992 4
1993 5
1994 1
1998 3
1999 4
2000 2
2001 4
2002 3
2003 4
2004 3
2005 4
2006 9
2007 12
2008 7
2009 10
2010 8
2011 6
2012 18
2013 23
2014 28
2015 33
2016 30
2017 31
2018 20
2019 13
2020 12
2021 2
Text availability
Article attribute
Article type
Publication date

Similar articles for PMID: 26598453

287 results
Results by year
Filters applied: . Clear all
Page 1
FDA Safety Reviews on Drugs, Biologics, and Vaccines: 2007-2013.
Cope JU, Rosenthal GL, Weinel P, Odegaard A, Murphy DM. Cope JU, et al. Pediatrics. 2015 Dec;136(6):1125-31. doi: 10.1542/peds.2015-0469. Pediatrics. 2015. PMID: 26598453 Review.
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT. Zhou W, et al. MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. MMWR Surveill Summ. 2003. PMID: 12825543 Free article.
Safety monitoring of drugs receiving pediatric marketing exclusivity.
Smith PB, Benjamin DK Jr, Murphy MD, Johann-Liang R, Iyasu S, Gould B, Califf RM, Li JS, Rodriguez W. Smith PB, et al. Pediatrics. 2008 Sep;122(3):e628-33. doi: 10.1542/peds.2008-0585. Pediatrics. 2008. PMID: 18762496 Free PMC article.
FDA working to ensure the safety of medical devices used in the pediatric population.
Flack MN, Gross TP, Reid JS, Mills TT, Francis J. Flack MN, et al. Pediatr Clin North Am. 2012 Dec;59(6):1355-66. doi: 10.1016/j.pcl.2012.08.003. Epub 2012 Oct 13. Pediatr Clin North Am. 2012. PMID: 23116531
FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
Roller ST, Pippins RR, Ngai JW. Roller ST, et al. Food Drug Law J. 2009;64(3):577-98. Food Drug Law J. 2009. PMID: 19999646
The FDA and drug safety: a proposal for sweeping changes.
Furberg CD, Levin AA, Gross PA, Shapiro RS, Strom BL. Furberg CD, et al. Arch Intern Med. 2006 Oct 9;166(18):1938-42. doi: 10.1001/archinte.166.18.1938. Arch Intern Med. 2006. PMID: 17030825
Food and Drug Administration (FDA) postmarket reported side effects and adverse events associated with pulmonary hypertension therapy in pediatric patients.
Maxey DM, Ivy DD, Ogawa MT, Feinstein JA. Maxey DM, et al. Pediatr Cardiol. 2013 Oct;34(7):1628-36. doi: 10.1007/s00246-013-0688-2. Epub 2013 Mar 27. Pediatr Cardiol. 2013. PMID: 23532466 Free PMC article.
Pediatric post-marketing safety systems in North America: assessment of the current status.
McMahon AW, Wharton GT, Bonnel R, DeCelle M, Swank K, Testoni D, Cope JU, Smith PB, Wu E, Murphy MD. McMahon AW, et al. Pharmacoepidemiol Drug Saf. 2015 Aug;24(8):785-92. doi: 10.1002/pds.3813. Epub 2015 Jun 22. Pharmacoepidemiol Drug Saf. 2015. PMID: 26098297 Review.
A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.
Hoffman KB, Dimbil M, Kyle RF, Tatonetti NP, Erdman CB, Demakas A, Chen D, Overstreet BM. Hoffman KB, et al. J Manag Care Spec Pharm. 2015 Dec;21(12):1134-43. doi: 10.18553/jmcp.2015.21.12.1134. J Manag Care Spec Pharm. 2015. PMID: 26679963
Post-licensure rapid immunization safety monitoring program (PRISM) data characterization.
Baker MA, Nguyen M, Cole DV, Lee GM, Lieu TA. Baker MA, et al. Vaccine. 2013 Dec 30;31 Suppl 10:K98-112. doi: 10.1016/j.vaccine.2013.04.088. Vaccine. 2013. PMID: 24331080
287 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback